Cover Story Current Issue

Obesity affects a significant fraction of the world population, with some states or countries reporting overwhelming majority of the population as obese or overweight. Effective treatments were not readily available until the recent approval of glucagon-like peptide-1 (GLP-1) -based pharmacotherapeutics for weight loss. Since then, the use of GLP-1-based pharmacotherapies for the treatment of obesity has skyrocketed. In addition to or because of the effective weight loss, these medications affect many different organs in the body. Many of these effects, including the degree of weight loss achieved, show significant sex differences. Moreover, recent analysis of online patient communities identified a range of self-reported reproductive and endocrine side effects of GLP-1 based therapies including menstrual irregularities, reduced libido, and hot-flashes that have not been systematically captured in clinical trials. Some of these reports contrast with recent data indicating that in Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly Polycystic Ovary Syndrome) patients semaglutide-associated weight loss normalizes menstrual cycles in most patients, leaving this issue unresolved. While it has been established that sex and sex hormones affect the action of GLP-1 analogues, whether these medications affect the levels of sex hormones and reproductive organs is less well understood, especially in a chronic and clinically relevant drug application setting.

Full text

 

Current Issue

Phosphomannomutase 1 restrains adipose thermogenic programming via inosine signaling

Yafen Ye, Rongrong Xu, Tianwen Liu, Yingying Su, ... Junfeng Han

Phosphomannomutase 1 restrains adipose thermogenic programming via inosine signaling

 

Objectives

Phosphomannomutase 1 (PMM1) is an evolutionarily conserved metabolic enzyme classically linked to mannose metabolism, but its physiological role in adipose tissue remains unknown. This study aimed to define the function of PMM1 in thermogenic regulation and systemic metabolism.

Methods

An unbiased, integrative transcriptomic analysis of human subcutaneous adipose tissue was performed to relate PMM1 expression to clinical measures. Functional studies in mice and in primary murine and human adipocytes with PMM1 loss- and gain-of-function were conducted to investigate PMM1's role in the thermogenic program, assessed by metabolic phenotyping, RNA sequencing, targeted metabolomics, and signaling assays.

Results

PMM1 expression was inversely associated with obesity-related anthropometric and biochemical measures and was markedly induced by thermogenic stimulation. Adipocyte-specific Pmm1 knockdown promoted adipose thermogenic remodeling, increased energy expenditure, and protected mice from diet-induced obesity and insulin resistance. Mechanistically, PMM1 deficiency rerouted glucose metabolism into the pentose phosphate pathway, increasing inosine monophosphate and extracellular inosine. The elevated inosine engaged adenosine A2A/A2B receptors, activated the PKA–CREB signaling cascade, and enhanced a thermogenic program in both murine and human adipocytes. Pharmacologic blockade of A2A/A2B receptors or PKA abrogated these effects, confirming the requirement of inosine signaling. In contrast, PMM1 overexpression in primary adipocytes blunted thermogenic activation.

Conclusions

PMM1 functions as a key metabolic brake on the adipose thermogenic program by limiting inosine production and downstream A2A/A2B–PKA signaling. These findings reveal a previously unrecognized PMM1–inosine regulatory pathway linking purine metabolism to energy homeostasis and identify PMM1 as a potential therapeutic target for obesity and related metabolic disorders.

 

 

Articles in Press

Phosphomannomutase 1 restrains adipose thermogenic programming via inosine signaling

Yafen Ye, Rongrong Xu, Tianwen Liu, Yingying Su, ... Junfeng Han

Phosphomannomutase 1 restrains adipose thermogenic programming via inosine signaling

 

Objectives

Phosphomannomutase 1 (PMM1) is an evolutionarily conserved metabolic enzyme classically linked to mannose metabolism, but its physiological role in adipose tissue remains unknown. This study aimed to define the function of PMM1 in thermogenic regulation and systemic metabolism.

Methods

An unbiased, integrative transcriptomic analysis of human subcutaneous adipose tissue was performed to relate PMM1 expression to clinical measures. Functional studies in mice and in primary murine and human adipocytes with PMM1 loss- and gain-of-function were conducted to investigate PMM1's role in the thermogenic program, assessed by metabolic phenotyping, RNA sequencing, targeted metabolomics, and signaling assays.

Results

PMM1 expression was inversely associated with obesity-related anthropometric and biochemical measures and was markedly induced by thermogenic stimulation. Adipocyte-specific Pmm1 knockdown promoted adipose thermogenic remodeling, increased energy expenditure, and protected mice from diet-induced obesity and insulin resistance. Mechanistically, PMM1 deficiency rerouted glucose metabolism into the pentose phosphate pathway, increasing inosine monophosphate and extracellular inosine. The elevated inosine engaged adenosine A2A/A2B receptors, activated the PKA–CREB signaling cascade, and enhanced a thermogenic program in both murine and human adipocytes. Pharmacologic blockade of A2A/A2B receptors or PKA abrogated these effects, confirming the requirement of inosine signaling. In contrast, PMM1 overexpression in primary adipocytes blunted thermogenic activation.

Conclusions

PMM1 functions as a key metabolic brake on the adipose thermogenic program by limiting inosine production and downstream A2A/A2B–PKA signaling. These findings reveal a previously unrecognized PMM1–inosine regulatory pathway linking purine metabolism to energy homeostasis and identify PMM1 as a potential therapeutic target for obesity and related metabolic disorders.

 

 

2025 Impact Factor: 6.3

You are what you eat

Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.

Auf Werbeinhalte, die vor, während oder nach Videos von WEBSITE-URL eingeblendet werden, hat WEBSITE-URL keinen Einfluss. Wir übernehmen keine Gewähr für diese Inhalte. Weitere Informationen finden Sie hier.